Your browser doesn't support javascript.
loading
Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay, Joseph P; Smith, Rebecca; Devlin, Kaylyn; Hollern, Daniel P; Liby, Tiera; Liu, Moqing; Boddapati, Shanta; Watson, Spencer S; Esch, Amanda; Zheng, Ting; Thompson, Wallace; Babcock, Darcie; Kwon, Sunjong; Chin, Koei; Heiser, Laura; Gray, Joe W; Korkola, James E.
Afiliação
  • Garay JP; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Smith R; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Devlin K; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Hollern DP; Department of Genetics, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA.
  • Liby T; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Liu M; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Boddapati S; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Watson SS; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Esch A; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Zheng T; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Thompson W; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Babcock D; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Kwon S; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Chin K; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Heiser L; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
  • Gray JW; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA. grayjo@ohsu.edu.
  • Korkola JE; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA. korkola@ohsu.edu.
Breast Cancer Res ; 23(1): 81, 2021 08 03.
Article em En | MEDLINE | ID: mdl-34344439
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Resistencia a Medicamentos Antineoplásicos / Classe I de Fosfatidilinositol 3-Quinases Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Resistencia a Medicamentos Antineoplásicos / Classe I de Fosfatidilinositol 3-Quinases Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos